Sarcopenia treatment involves products that aid in the treatment of muscle loss disorder called Sarcopenia that commonly affects elderly population. Some key Sarcopenia Treatment products are vitamin D and calcium supplements, protein supplements, creatine supplements, and exercise therapy equipment.

Sarcopenia can severely impact the quality of life in aging adults by weakening muscles and increasing risks of falls and related injuries. Thus, there has been significant focus on developing effective Sarcopenia Treatment Market Demand to counter sarcopenia.

The Global Sarcopenia Treatment Market is estimated to be valued at US$ 3.47 billion in 2024 and is expected to exhibit a CAGR of 9.5% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Sarcopenia Treatment Market are Yokogawa, General Electric, Rockwell Automation, MAVERICK Technologies, Emerson, Siemens, Rudolph Technologies, Honeywell International, ABB, Schneider Electric, Aspen Technology. The increasing commercialization of innovative products for sarcopenia treatment by these companies is expected to drive the market growth.

The rising elderly population globally is resulting in high prevalence of age-related conditions like sarcopenia. As per estimates, over 50% of the population in developed countries will be aged by 2050. This growing geriatric base is fueling the demand for sarcopenia treatment products.

The market players are also focusing on expanding their geographical presence through strategic collaboration and partnerships to address the needs of underexplored regional sarcopenia markets. For instance, in 2021, Yokogawa partnered with a Chinese pharmaceutical company to develop novel therapeutics targeting sarcopenia in Asia Pacific.

Market Key Trends

Adoption of digital therapy is one of the key trends being observed in the Sarcopenia Treatment Market Size. Various developers are integrating virtual reality, internet of things, and mobile apps into traditional exercise and dietary programs for sarcopenia. This enables remote monitoring of patients as well as enhances adherence to the prescribed therapy regimen. Focus on digital therapeutics is expected to make sarcopenia treatment more effective and accessible in the upcoming years.

Porter’s Analysis

Threat of new entrants: Low barrier for new drug/biologic development however long timeline and costs associated with clinical trials poses significant threat.

Bargaining power of buyers: Large pharmaceutical companies have significant bargaining power over biotech/small pharma players developing sarcopenia drugs due to scale and marketing capabilities.

Bargaining power of suppliers: Supply of raw materials required for sarcopenia drug development process is consolidated among few players providing them with significant bargaining power.

Threat of new substitutes: Emergence of alternative therapeutics like nutraceuticals, lifestyle interventions and combination therapies pose threat to existing sarcopenia treatment options.

Competitive rivalry: Presence of many pipeline drugs in clinical trials promotes competition in sarcopenia treatment landscape.

Geographical Regions

North America region currently holds largest share of sarcopenia treatment market value owing to high diagnosed patient population and greater adoption of prescription therapies. Growing elderly population and increasing healthcare spending further consolidates region’s prominence.

Asia Pacific region is poised to witness fastest growth during forecast period owing to changing demographics, rising medical standards and growing healthcare expenditures of economies like China and India. Supportive regulatory guidelines will also aid regional market expansion.

For Enhanced Understanding, Dive into the Report in the Language that Connects with You

• French
• German
• Italian
• Russian
• Japanese
• Chinese
• Korean
• Portuguese

*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it

The post Sarcopenia Treatment Market is poised to be valued at US$3.47 billion by 2024 owing to increasing R&D investments appeared first on .